Gabapentin 100mg Blister
Gabapentin Capsule
Product Images NDC 67877-222
11 FDA label images from Ascend Laboratories, Llc · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 67877-222). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Gabapentin-100mg-cap (Gabapentin 100mg Cap)
Gabapentin 300mg Blister
Gabapentin-300mg-cap (Gabapentin 300mg Cap)
Gabapentin 400mg Blister
Gabapentin-400mg-cap (Gabapentin 400mg Cap)
Gabapentin-equation (Gabapentin Equation)
A formula showing the calculation for creatinine clearance (CLCr), including variables for age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplication factor for female patients. The formula is presented as text on a white background.*
Gabapentin Fig1
Line graph depicting mean pain score over 8 weeks comparing placebo and Gabapentin (3600 mg/day). The x-axis represents weeks including a 4-week dose titration period and a 4-week fixed dose period. The y-axis represents mean pain score from 0 to 10. Gabapentin shows a decreasing pain score trend, while placebo remains relatively stable.*
Gabapentin Fig2
Line graph showing mean pain scores over a 7-week period comparing placebo with gabapentin at 1800 mg/day and 2400 mg/day. The graph includes a 3-week dose titration period followed by a 4-week fixed dose period, illustrating changes in pain scores from baseline through week 7 for each group.*
Gabapentin Fig3
A bar chart titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' compares responder proportions in two studies. Study 1 shows 12% for placebo and 29% for Gabapentin 3600 mg. Study 2 shows 14% for placebo, 32% for Gabapentin 1800 mg, and 34% for Gabapentin 2400 mg, with significance levels indicated (p < 0.01, p < 0.001).*
Gabapentin-fig4 (Gabapentin Fig4)
A chart showing the percentage difference on the y-axis versus daily dose in milligrams on the x-axis for gabapentin. The graph includes data points from three different studies labeled a, b, and c, with Study a represented by black squares, Study b by gray squares, and Study c by white squares, showing comparative values at doses 600 mg, 900 mg, 1200 mg, and 1800 mg.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
